"Ocugen, Inc. Completes Dosing for Phase 1/2 Trial of OCU410 for Geographic Atrophy"

Ocugen, Inc. completes dosing in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy candidate for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). The trial aims to assess the safety and efficacy of OCU410, which targets multiple pathways causing dAMD, including complement, lipid metabolism, inflammation, and oxidative stress. The company is optimistic about the potential of OCU410 as a one-time treatment for GA and plans to continue providing clinical updates as the trial progresses.